BioVeris Completes Merger With Roche
BioVeris Corporation announced that on June 25, 2007 the Company's stockholders voted to approve Roche's acquisition of BioVeris, and that the transaction was completed.
The acquisition will allow Roche Diagnostics to expand its immunochemistry business from the human diagnostic field into new market segments such as life science research, life science development, patient self testing, veterinary testing, drug discovery, drug development and clinical trials. By acquiring BioVeris, Roche will own the complete patent estate of the electrochemiluminescence (ECL) technology deployed in its Elecsys product line which gives Roche Diagnostics the opportunity to fully exploit the entire immunochemistry market.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Fyodor_Dostoevsky
Comorbidity
Strand Genomics and MediBIC form business partnership - bioinformatics and data mining solutions in Japan

Finding new weapons in Nature`s battlesites - Genomic studies open up a wealth of bioactive small molecules in insect-killing bacteria
Ultraviolet_germicidal_irradiation
Heart_murmur
Category:Bone_morphogenetic_protein
Neuromuscular_junction
Richard_Jadick
New material with built-in vitamin A may reduce scarring
Gefitinib
